Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Depreciation & Amortization (CF) (2017 - 2025)

Protagonist Therapeutics' Depreciation & Amortization (CF) history spans 9 years, with the latest figure at $376000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 218.64% year-over-year to $376000.0; the TTM value through Dec 2025 reached $1.3 million, up 54.96%, while the annual FY2025 figure was $1.3 million, 54.96% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $376000.0 at Protagonist Therapeutics, up from $361000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $376000.0 in Q4 2025 and bottomed at $118000.0 in Q4 2024.
  • The 5-year median for Depreciation & Amortization (CF) is $242500.0 (2023), against an average of $246500.0.
  • The largest annual shift saw Depreciation & Amortization (CF) crashed 52.42% in 2024 before it soared 218.64% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $235000.0 in 2021, then grew by 8.94% to $256000.0 in 2022, then decreased by 3.12% to $248000.0 in 2023, then plummeted by 52.42% to $118000.0 in 2024, then skyrocketed by 218.64% to $376000.0 in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Depreciation & Amortization (CF) are $376000.0 (Q4 2025), $361000.0 (Q3 2025), and $304000.0 (Q2 2025).